Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384283077> ?p ?o ?g. }
- W4384283077 endingPage "558" @default.
- W4384283077 startingPage "549" @default.
- W4384283077 abstract "Rationale: Chronic obstructive pulmonary disease (COPD) exacerbations are a major cause of morbidity and mortality, and preventing them is a key treatment target. Long-term macrolide treatment is effective at reducing exacerbations, but there is a paucity of evidence for other antibiotic classes. Objectives: To assess whether 12-month use of doxycycline reduces the exacerbation rate in people with COPD. Methods: People with moderate to very severe COPD and an exacerbation history were recruited from three UK centers and randomized to 12 months of doxycycline 100 mg once daily or placebo. The primary study outcome was the exacerbation rate per person-year. Results: A total of 222 people were randomized. Baseline mean FEV1 was 1.35 L (SD, 0.35 L), 52.5% predicted (SD, 15.9% predicted). The median number of treated exacerbations in the year before the study was 2 (SD, 1-4). A total of 71% of patients reported two or more exacerbations, and 81% were already prescribed inhaled corticosteroids at baseline. The COPD exacerbation rate did not differ between the groups (doxycycline/placebo rate ratio [RR], 0.86; 95% confidence interval [CI], 0.67-1.10; P = 0.23). No difference was seen if only treated exacerbations or hospitalizations were considered. In preplanned subgroup analysis, doxycycline appeared to better reduce the exacerbation rate among people with severe COPD (RR, 0.36; 95% CI, 0.15-0.85; P = 0.019) and in those with an eosinophil count <300 cells/μl (RR, 0.50; 95% CI, 0.29-0.84; P = 0.01). Health status measured by St. George's Respiratory Questionnaire was 5.2 points worse in the doxycycline group at 12 months (P < 0.007). Conclusions: Doxycycline did not significantly reduce the exacerbation rate, over 12 months, in participants with COPD who exacerbated regularly, but it may have benefitted those with more severe COPD or blood eosinophil counts <300 cells/μl. Clinical trial registered with www.clinicaltrials.gov (NCT02305940)." @default.
- W4384283077 created "2023-07-15" @default.
- W4384283077 creator A5002250762 @default.
- W4384283077 creator A5007976050 @default.
- W4384283077 creator A5009749739 @default.
- W4384283077 creator A5010964879 @default.
- W4384283077 creator A5018497648 @default.
- W4384283077 creator A5020191448 @default.
- W4384283077 creator A5040741400 @default.
- W4384283077 creator A5042998672 @default.
- W4384283077 creator A5060938388 @default.
- W4384283077 creator A5073845417 @default.
- W4384283077 creator A5085320265 @default.
- W4384283077 date "2023-09-01" @default.
- W4384283077 modified "2023-10-17" @default.
- W4384283077 title "A Double-Blind, Randomised, Placebo-controlled Trial of Long-Term Doxycycline Therapy on Exacerbation Rate in Patients with Stable COPD" @default.
- W4384283077 cites W1811879327 @default.
- W4384283077 cites W1970234910 @default.
- W4384283077 cites W1976295332 @default.
- W4384283077 cites W1976378044 @default.
- W4384283077 cites W1991648511 @default.
- W4384283077 cites W1993396326 @default.
- W4384283077 cites W1996626562 @default.
- W4384283077 cites W2039331633 @default.
- W4384283077 cites W2041092088 @default.
- W4384283077 cites W2044448067 @default.
- W4384283077 cites W2044782575 @default.
- W4384283077 cites W2065302886 @default.
- W4384283077 cites W2067349568 @default.
- W4384283077 cites W2096373158 @default.
- W4384283077 cites W2102634938 @default.
- W4384283077 cites W2102856718 @default.
- W4384283077 cites W2108424624 @default.
- W4384283077 cites W2110152822 @default.
- W4384283077 cites W2111497869 @default.
- W4384283077 cites W2112162293 @default.
- W4384283077 cites W2112686581 @default.
- W4384283077 cites W2117837864 @default.
- W4384283077 cites W2125078269 @default.
- W4384283077 cites W2131368844 @default.
- W4384283077 cites W2137969357 @default.
- W4384283077 cites W2144974876 @default.
- W4384283077 cites W2149849734 @default.
- W4384283077 cites W2172046332 @default.
- W4384283077 cites W2324038222 @default.
- W4384283077 cites W2365138737 @default.
- W4384283077 cites W2562304717 @default.
- W4384283077 cites W2583265473 @default.
- W4384283077 cites W2595161845 @default.
- W4384283077 cites W2604501983 @default.
- W4384283077 cites W2606386702 @default.
- W4384283077 cites W2610509046 @default.
- W4384283077 cites W2783705291 @default.
- W4384283077 cites W2794699839 @default.
- W4384283077 cites W2920797638 @default.
- W4384283077 cites W2982543168 @default.
- W4384283077 cites W3020736525 @default.
- W4384283077 cites W4206187060 @default.
- W4384283077 cites W4233317660 @default.
- W4384283077 cites W4247768401 @default.
- W4384283077 cites W4256713179 @default.
- W4384283077 doi "https://doi.org/10.1164/rccm.202212-2287oc" @default.
- W4384283077 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37450935" @default.
- W4384283077 hasPublicationYear "2023" @default.
- W4384283077 type Work @default.
- W4384283077 citedByCount "1" @default.
- W4384283077 countsByYear W43842830772023 @default.
- W4384283077 crossrefType "journal-article" @default.
- W4384283077 hasAuthorship W4384283077A5002250762 @default.
- W4384283077 hasAuthorship W4384283077A5007976050 @default.
- W4384283077 hasAuthorship W4384283077A5009749739 @default.
- W4384283077 hasAuthorship W4384283077A5010964879 @default.
- W4384283077 hasAuthorship W4384283077A5018497648 @default.
- W4384283077 hasAuthorship W4384283077A5020191448 @default.
- W4384283077 hasAuthorship W4384283077A5040741400 @default.
- W4384283077 hasAuthorship W4384283077A5042998672 @default.
- W4384283077 hasAuthorship W4384283077A5060938388 @default.
- W4384283077 hasAuthorship W4384283077A5073845417 @default.
- W4384283077 hasAuthorship W4384283077A5085320265 @default.
- W4384283077 hasBestOaLocation W43842830771 @default.
- W4384283077 hasConcept C126322002 @default.
- W4384283077 hasConcept C142724271 @default.
- W4384283077 hasConcept C167704817 @default.
- W4384283077 hasConcept C168563851 @default.
- W4384283077 hasConcept C204787440 @default.
- W4384283077 hasConcept C27081682 @default.
- W4384283077 hasConcept C2776780178 @default.
- W4384283077 hasConcept C2777014857 @default.
- W4384283077 hasConcept C2777179404 @default.
- W4384283077 hasConcept C44249647 @default.
- W4384283077 hasConcept C501593827 @default.
- W4384283077 hasConcept C71924100 @default.
- W4384283077 hasConcept C82789193 @default.
- W4384283077 hasConcept C86803240 @default.
- W4384283077 hasConcept C89423630 @default.
- W4384283077 hasConceptScore W4384283077C126322002 @default.
- W4384283077 hasConceptScore W4384283077C142724271 @default.
- W4384283077 hasConceptScore W4384283077C167704817 @default.